These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 27649551)

  • 1. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
    Tang C; Welsh JW; de Groot P; Massarelli E; Chang JY; Hess KR; Basu S; Curran MA; Cabanillas ME; Subbiah V; Fu S; Tsimberidou AM; Karp D; Gomez DR; Diab A; Komaki R; Heymach JV; Sharma P; Naing A; Hong DS
    Clin Cancer Res; 2017 Mar; 23(6):1388-1396. PubMed ID: 27649551
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.
    Welsh JW; Tang C; de Groot P; Naing A; Hess KR; Heymach JV; Papadimitrakopoulou VA; Cushman TR; Subbiah V; Chang JY; Simon GR; Ramapriyan R; Barsoumian HB; Menon H; Cortez MA; Massarelli E; Nguyen Q; Sharma P; Allison JP; Diab A; Verma V; Raju U; Shaaban SG; Dadu R; Cabanillas ME; Wang K; Anderson C; Gomez DR; Hahn S; Komaki R; Hong DS
    Cancer Immunol Res; 2019 Dec; 7(12):1903-1909. PubMed ID: 31658994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease.
    He K; Hong DS; Tang C; Sezen D; Cox L; Maleki A; Bertolet G; Nguyen QN; Comeaux NI; Schuda L; Chen D; Welsh JW
    Radiother Oncol; 2023 Jun; 183():109618. PubMed ID: 36921766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Zheng Y; Shi A; Wang W; Yu H; Yu R; Li D; Xu B; Ma H; You J; Zhao D; Jiang L; Geng J; Zhu G
    Clin Lung Cancer; 2018 Jul; 19(4):e399-e404. PubMed ID: 29519614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
    Yi JS; Ready N; Healy P; Dumbauld C; Osborne R; Berry M; Shoemaker D; Clarke J; Crawford J; Tong B; Harpole D; D'Amico TA; McSherry F; Dunphy F; McCall SJ; Christensen JD; Wang X; Weinhold KJ
    Clin Cancer Res; 2017 Dec; 23(24):7474-7482. PubMed ID: 28951518
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.
    Liu C; Hu Q; Hu K; Su H; Shi F; Kong L; Zhu H; Yu J
    J Transl Med; 2019 Apr; 17(1):120. PubMed ID: 30971280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.
    Boutros C; Chaput-Gras N; Lanoy E; Larive A; Mateus C; Routier E; Sun R; Tao YG; Massard C; Bahleda R; Schwob D; Ibrahim N; Khoury Abboud RM; Caramella C; Lancia A; Cassard L; Roy S; Soria JC; Robert C; Deutsch E
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma.
    Sundahl N; De Wolf K; Kruse V; Meireson A; Reynders D; Goetghebeur E; Van Gele M; Speeckaert R; Hennart B; Brochez L; Ost P
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):906-915. PubMed ID: 29485070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in systemic immune response after stereotactic ablative radiotherapy. Preliminary results of a prospective study in patients with early lung cancer.
    Rutkowski J; Ślebioda T; Kmieć Z; Zaucha R
    Pol Arch Intern Med; 2017 Apr; 127(4):245-253. PubMed ID: 28420863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
    Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
    Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials.
    Verma V; Cushman TR; Selek U; Tang C; Welsh JW
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1141-1148. PubMed ID: 30012526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
    Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.
    Brooks ED; Sun B; Zhao L; Komaki R; Liao Z; Jeter M; Welsh JW; O'Reilly MS; Gomez DR; Hahn SM; Heymach JV; Rice DC; Chang JY
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):900-907. PubMed ID: 28258887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
    Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA.
    Sanuki N; Takeda A; Oku Y; Eriguchi T; Nishimura S; Aoki Y; Mizuno T; Iwabuchi S; Kunieda E
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):306-11. PubMed ID: 24411601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
    Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
    J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.